Severe Thrombocytopenia, Extreme Erythroblastosis and Capillary Leak Syndrome in a Metastatic Melanoma Patient. Concurrent Pembrolizumab- and Lenvatinib-Associated Toxicities.

Ítems similars

• Severe Thrombocytopenia, Extreme Erythroblastosis and Capillary Leak Syndrome in a Metastatic Melanoma Patient. Concurrent Pembrolizumab- and Lenvatinib-Associated Toxicities.
  per: I. Patsialos, et al.
  Publicat: (2026-01-01)
• Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
  per: Georgios Lyrarakis, et al.
  Publicat: (2024-10-01)
• Long term treatment of advanced endometrial cancer with lenvatinib and pembrolizumab
  per: Sahana Somasegar, et al.
  Publicat: (2025-04-01)
• Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity
  per: Nicoletta Staropoli, et al.
  Publicat: (2023-07-01)
• Acute vascular and cardiac effects of lenvatinib in mice
  per: Dustin N. Krüger, et al.
  Publicat: (2025-02-01)